Data fra flere kliniske undersøgelser viste, at den samlede forekomst af opportunistiske infektioner var 0, 09% for de 15. 402 patienter, som blev behandlet med Enbrel.
In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel.